Related Experiment Video

Updated: Dec 18, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.1K

SRC Promotes Tamoxifen Resistance in Breast Cancer via Up-Regulating SIRT1

Jun Zhou1, Ming Xu1, Kehao Le1

  • 1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People's Republic of China.

Oncotargets and Therapy
|June 18, 2020
PubMed
Abstract

Insights

SRC and SIRT1 are elevated in tamoxifen-resistant breast cancer, correlating with poor patient survival. Targeting SRC and SIRT1 may offer new therapeutic strategies for overcoming tamoxifen resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Endocrine therapy is crucial for estrogen receptor-positive breast cancer.
  • Tamoxifen resistance presents a significant clinical challenge.
  • Understanding resistance mechanisms is vital for developing new treatments.

Purpose of the Study:

  • To investigate SRC and SIRT1 expression changes in tamoxifen-resistant breast cancer cells.
  • To elucidate the functional roles of SRC and SIRT1 in tamoxifen resistance.
  • To explore SRC and SIRT1 as potential therapeutic targets.

Main Methods:

  • Gene expression analysis using RNA sequencing, qPCR, and Western blotting.
  • In vitro and in vivo loss- and gain-of-function studies of SRC and SIRT1.
  • Survival analysis using Kaplan-Meier and receiver operating characteristic curves.

Main Results:

  • High SRC and/or SIRT1 expression is linked to poor survival in tamoxifen-treated patients.
  • Down-regulating SRC or SIRT1 reversed tamoxifen resistance.
  • SRC and SIRT1 inhibitors suppressed cancer cell proliferation.
  • SRC overexpression promotes tamoxifen resistance, partly via up-regulating SIRT1.

Conclusions:

  • SRC and SIRT1 are upregulated in tamoxifen-resistant breast cancer and associated with poor prognosis.
  • SRC promotes tamoxifen resistance by upregulating SIRT1.
  • SRC and SIRT1 represent potential therapeutic targets for tamoxifen-resistant breast cancer.
Keywords:
SIRT1SRCbreast cancerinhibitortamoxifen resistance

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K